Fetomaternal outcomes of mothers with detectable cytomegalo virus (CMV)-specific IgM antibodies


  • Saima Wani Department of Obstetrics and Gynaecology, SKIMS, Soura, Srinagar, Jammu and Kashmir, India
  • Shaheera Ajaz Department of Obstetrics and Gynaecology, SKIMS, Soura, Srinagar, Jammu and Kashmir, India
  • Tashaffi Qayoom Department of Obstetrics and Gynaecology, SKIMS, Soura, Srinagar, Jammu and Kashmir, India




Abortion, Cytomegalovirus, Feto maternal outcome, Pregnancy


Background: Human cytomegalovirus (CMV) infection is the most common cause of perinatal viral infection. congenital CMV infection can produce varying degrees of neurodevelopmental disabilities. Aims and objectives were to study the fetomaternal outcome in CMV-Specific IgM antibodies.

Methods: The study was prospective for a period of one and a half year. Hundred high risk patients with hundred controls were screened for CMV serology IgM. Maternal & fetal outcomes were noted.

Results: Out of 100 cases in study group 27(27%) were positive for CMV IgM while in control group 6(6%) were positive(p<0.05). Primary CMV infection in mothers led to abortion in 2(7.4%) patients, pre-term labour in 5(18.5%), Postpartum hemorrhage in 6 (22.2%), fetal distress in 11(40.7%) while 37% had uneventful outcome. Among CMV positive cases 48.1% were born term live, 6(22.2%) were preterm, 1(3.7%) had IUD, Intrauterine growth restriction in 10 (37%), 6(22.2%) with congenital defect and 4(14.8%) with neonatal manifestations.

Conclusions: CMV remains a significant public health concern. Education of young women in our community regarding hygienic and behavioral approaches that can help prevent CMV transmission is mandatory.


Stagno S, Tinker MK, Etrod C, Fuccillo DA, Cloud G, O’Beeree AJ Immunoglobulin M antibodies detected by enzyme linked radioimmunoassay in the diagnosis of cytomegalovirus in pregnant women and newborn infants. J Clinical Microbiol. 1985;21(6):930-53.

Adler SP, Cytomegalovirus and child care day workers. Evidence for an increased infection rate among day care workers. N-Engl J. Med. 1989;321:1290-6.

Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis. 1995;20:665-70.

Fisher S, Genbacev O, Maidji E, Pereira L. Human Cytomegalovirus Infection of Placental Cytotrophoblasts In Vitro and In Utero: Implications for Transmission and Pathogenesis, J Virol. 2000;74(15):6808-20.

Maine GT, Lazzarotto T, Landini MP. New developments in the diagnosis of maternal and congenital infection. Expert Rev Mol Diagn. 2001 May 1;1(1):19-29.

Rahav G, Gabbay R, Ornoy A, Shechtman S, Judith Arnon J, Diav-Citrin O. Primary versus Nonprimary Cytomegalovirus Infection during Pregnancy, Israel. EID. 2007 Nov;13(11):1791.

Koltsova IG. Interscience Conference on Antimicrobial Agents and Chemotherapy. TORCH Group Infections in Ukraine. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29;39:656.

Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus in relation to maternal antibody status. N Engl J Med. 1992;326:663-7.

Griffith P, Babbonian C. A prospective study of primary cytomegalovirus infection during pregnancy. final report. BJOG. 1984;91:307-15.

Gumber S, Arora U, Devi P. Occurrence of cytomegalo virus and herpes simplex virus infections in pregnancy. Indian J Med Microbiol. 2008;26:204-5.

Ornoy A, Diac- Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Oxicol. 2006;21:399-409.

Turbadkar D, Mathur M, Rele M, Seroprevalence of torch infection in bad obstetric history. Indian J Med Microbiol. 2003;21(2):108-10.

Duff P. Cytomegalovirus infection in pregnancy. Infec Dis Obst Gynecol. 1994;2:146-152.

Goderis J, Leenheer ED, Smets K, Van Hoecke H, Keymeulen A, Dhooge I. Hearing loss and congenital CMV infection: a systematic review. Pediatrics. 2014;134(5):972-82.

Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. New England J Med. 2015 Mar 5;372(10):933-43.




How to Cite

Wani, S., Ajaz, S., & Qayoom, T. (2019). Fetomaternal outcomes of mothers with detectable cytomegalo virus (CMV)-specific IgM antibodies. International Journal of Research in Medical Sciences, 7(6), 2157–2160. https://doi.org/10.18203/2320-6012.ijrms20192491



Original Research Articles